PINP as a biological response marker during teriparatide treatment for osteoporosis

Osteoporosis medication adherence: Physician perceptions vs. patients' utilization

(2013) Jeffrey R. Curtis et al.   BONE

Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial

(2013) Claus-C Glüer et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study

(2013) Adi Cohen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

(2013) Joy N Tsai et al.   LANCET

Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis

(2013) P. Farahmand et al.   OSTEOPOROSIS INTERNATIONAL

Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum

(2012) Marja-Kaisa Koivula et al.   CLINICAL BIOCHEMISTRY

Bone strength and surrogate markers: The first, second, and third fiddle

(2012) Paul D Miller   JOURNAL OF BONE AND MINERAL RESEARCH

Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene

(2012) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial

(2012) David W. Dempster et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bone turnover markers: use in osteoporosis

(2012) Kim Naylor et al.   Nature Reviews Rheumatology

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges

(2012) D. Bauer et al.   OSTEOPOROSIS INTERNATIONAL

Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis

(2011) JH Krege et al.   BONE

Clinical Utility of Serum Bone Turnover Markers in Postmenopausal Osteoporosis Therapy Monitoring: A Systematic Review

(2011) Thomas Funck-Brentano et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate

(2010) Alan L. Burshell et al.   BONE

Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases

(2010) Akimitsu Miyauchi et al.   BONE

PINP as an aid for monitoring patients treated with teriparatide

(2010) Mika Tsujimoto et al.   BONE

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide

(2010) A. Blumsohn et al.   OSTEOPOROSIS INTERNATIONAL

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

(2010) S. Vasikaran et al.   OSTEOPOROSIS INTERNATIONAL

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial

(2009) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy

(2009) Sarah J. Glover et al.   BONE

Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment

(2009) Sven Prevrhal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women

(2009) THE BonAdASIA STUDY GROUP   International Journal of Rheumatic Diseases

Improvements in Vertebral Body Strength Under Teriparatide Treatment Assessed In Vivo by Finite Element Analysis: Results From the EUROFORS Study

(2009) Christian Graeff et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis*

(2009) Robert R Recker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent

(2009) Felicia Cosman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis

(2009) J.-P. DEVOGELAER et al.   JOURNAL OF RHEUMATOLOGY

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status

(2009) B. L. Langdahl et al.   OSTEOPOROSIS INTERNATIONAL

Bone turnover markers: understanding their value in clinical trials and clinical practice

(2009) R. Civitelli et al.   OSTEOPOROSIS INTERNATIONAL

Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial

(2008) A. D. Anastasilakis et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate

(2008) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis

(2007) Steven Boonen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM